The lipophilic extracts of *Echinacea angustifolia* or *Zanthoxylum bungeanum* contain between 15 and 35%, preferably 25%, of isobutylamides, and are prepared with carbon dioxide under supercritical conditions as reported in EP 0464298 and WO 00/02570. Isobutylamides are ligands of the cannabinoid receptors, particularly CB2, and agonists of TRPV1, the vanilloid receptor with a painkilling function.

The extracts of *Serenoa repens, Zingiber officinalis* and *Echinacea angustifolia* or *Zanthoxylum bungeanum* are preferably present in the compositions according to the invention in the ratios of 1:0.25-0.5:0.05-0.1, which minimise the side effects and consequently allow safe chronic treatment.

The therapeutic effect was evaluated on the basis of internationally accepted scores according to the NIH-CPSI (National Institute of Health - Chronic Prostatitis Symptoms Index) which monitors CP-CPPS (chronic prostatitis/chronic pelvic pain syndrome), which is associated with urinary symptoms such as pollakiuria, dysuria, nocturia and sexual dysfunctions which have lasted for at least three to six months and are present in the absence of urogenital infections, tumours or anatomical abnormalities. The evaluations are functional in the absence of specific markers, and require an adequate number of patients. The scale comprises an NIH-CPSI range of 0 to 43 (43 for the most serious cases). A population with variations of 0 to 30 in the inclusion criteria was evaluated.

The trial was carried out on 80 patients aged between 55 and 70 years (63±7) with category IIIB CPPS. The patients were divided into 4 groups after randomisation; the first group was treated with capsules of *Serenoa repens* lipophilic extract (120 mg, 3 capsules a day), the second with the combination described in example 1 (3 capsules a day), the third with the mixture of *Echinacea angustifolia/Zingiber officinalis* lipophilic extract (3 capsules a day) prepared as described in EP 2379095 and administered in groundnut oil, and the fourth with a placebo. The data are reported in Table 1.

CLAIMS

1. Compositions comprising a *Serenoa repens* extract, a *Zingiber officinalis* lipophilic extract and an *Echinacea angustifolia* ~~or *Zanthoxylum bungeanum*~~ lipophilic extract.

2. Compositions according to claim 1 wherein the extracts of *Serenoa repens, Zingiber officinalis*~~,~~ *and Echinacea angustifolia* ~~and *Zanthoxylum bungeanum*~~ are prepared by extraction with supercritical carbon dioxide.

3. Compositions according to claim 1 or 2 wherein the *Serenoa repens* extract: *Zingiber officinalis* lipophilic extract: *Echinacea angustifolia* ~~or *Zanthoxylum bungeanum*~~ lipophilic extract ratios are 1:0.25-0.5:0.05-0.1.

4. Compositions according to one or more of claims 1 to 3 further comprising oils rich in ω-3 fatty acids.

5. Compositions according to claim 4 wherein the oils are selected from *Oenothera biennis*, *Linum usitatissimum* or *Ribes nigrum* oils and natural or semi-synthetic fish oils.

6. Compositions according to one or more of claims 1 to 5 further containing antioxidants and trace elements.

7. The compositions of claims 1-6 for use in the treatment of urinary incontinence, benign prostate hypertrophy, prostatitis and prostatism, and pelvic pain.

8. Use of the compositions according to any one of claims 1-6 in the manufacture of a medicament for the treatment of urinary incontinence, benign prostate hypertrophy, prostatitis and prostatism, and pelvic pain.